0001564590-22-011827.txt : 20220325 0001564590-22-011827.hdr.sgml : 20220325 20220325170035 ACCESSION NUMBER: 0001564590-22-011827 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220325 ITEM INFORMATION: Other Events FILED AS OF DATE: 20220325 DATE AS OF CHANGE: 20220325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 22772180 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 8-K 1 adpt-8k_20220325.htm 8-K adpt-8k_20220325.htm
false 0001478320 0001478320 2022-03-25 2022-03-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2022

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Washington

001-38957

27-0907024

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

1165 Eastlake Avenue East

Seattle, Washington

 

98109

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01

Other Events

 

Resignation of Chief Medical Officer

 

Lance Baldo resigned as Chief Medical Officer of Adaptive Biotechnologies Corporation (the “Company”), effective March 25, 2022, to pursue a new opportunity. Dr. Baldo stated that he does not have any disagreement with the Company, its management, its board of directors or any committee thereof on any matter.  


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Adaptive Biotechnologies Corporation

 

 

 

 

Date: March 25, 2022

 

By:

/s/ Chad Robins

 

 

 

Chad Robins

 

 

 

Chief Executive Officer

 

 

 

 

 EX-101.SCH 2 adpt-20220325.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 adpt-20220325_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 adpt-20220325_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Mar. 25, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 25, 2022
Entity Registrant Name ADAPTIVE BIOTECHNOLOGIES CORPORATION
Entity Central Index Key 0001478320
Entity Incorporation, State or Country Code WA
Entity File Number 001-38957
Entity Tax Identification Number 27-0907024
Entity Address, Address Line One 1165 Eastlake Avenue East
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98109
City Area Code 206
Local Phone Number 659-0067
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ADPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 adpt-8k_20220325_htm.xml IDEA: XBRL DOCUMENT 0001478320 2022-03-25 2022-03-25 false 0001478320 8-K 2022-03-25 ADAPTIVE BIOTECHNOLOGIES CORPORATION WA 001-38957 27-0907024 1165 Eastlake Avenue East Seattle WA 98109 206 659-0067 false false false false Common stock, par value $0.0001 per share ADPT NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !&(>50'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 1B'E4" M\[>T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)TW10^CVLN))07!!\1:2V=U@TX1DI-VW-XV[740?P&-F_GSS M#4RG@]0^XG/T 2-93#>S&\8D==BP(U&0 $D?T:E4Y\28FWL?G:+\C <(2G^H M X+@_ X.K@"%AAA=.F[@&8EENJ?V-(!=D[.R:ZI:9KJJ2VYO$,#;T^/+V7=RHZ) MU*@Q_TI6TBG@AETFO[;;^]T#ZP47HN)M)6YWHI&5297)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M$8AY5.$$P#I/! 8! !@ !X;"]W;W)K(8XSJYGLS&-WX6']S>Q @X+X_.D5Y)&6ZE>M$;S@UY2^)4W[0VQF0?'4>'&YXP?24S MGL*3E50),]!4:T=GBK.H"$IBA[INUTF82%NC87$O4*.AS$TL4AXHHO,D8>K] MEL=R>]/R6H<;3V*],?:&,QIF;,WGW/R>!0I:3JD2B82G6LB4*+ZZ:?G>QUO: MM@'%&]\$W^JC:V*[LI3RQ3:FT4W+M40\YJ&Q$@Q^7OF8Q[%5 H[O>]%6^4T; M>'Q]4+\O.@^=63+-QS)^%I'9W+3Z+1+Q%+:( 3J:W*W"AX*B#.C.YDF$.2#6%I1":I$>:=3--=M2%K0\? 1^RK3K@7 MO-T)TA."7YFZ(K1S0:A+Z3_#'6 K 6D)2 N]ZQ-Z8_G*%?G37VJCH(1_(9+7 MI>1U(=ENZO/B/>-U/<3#^Y=?$(AV"=%&57P@B J*^YBMZRCP^!6+-48%5SI4_J'@',)[$7/RF"=+KNI < W(V.5U?]#I(3R>6[FB>P[1 M@KV1:03U%"L1%HE#^!HD:>_2';@]E[8QPB/?]LXA]*-(<:TO#A?D =XCL[2V ME V2GM?MD G3)F8OG/BO/,UYT<: *Q_WZ'\"'ML6C+^%W-8O,[CN3B6NB$\.K5@D/M_D?T0*I#7C+'R([.6$;% =] MSQU@;-7*X>&&7U30A[W@:11<@+I=#*1:)CSCC,K]UN##9$L-6;K58GZH?K-9'1ROPI[M3_ M(IMJG0-9$V"#;"-@Y?T4-^J% .64QN/[/[I7=@Y ,^JLW3*'<1UMYW+,7BD5V_,W?DZ6L'7T- OY= ML,!(*L>GN#L?4D8F;^&&I6M^VK7;'V5W#R*PX0BZE@0-I M<;GA#":#?0&>KZ0TAX8]E9;_5!C]#5!+ P04 " 1B'E4GZ ;\+$" #B M# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[ M=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2Q MQ'DJ?$,78&F? KP(&K X MU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_P MZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8Q MA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R M]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#. MRW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV0 M3NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_ MAOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#% MZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[ MC>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS M/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " 1 MB'E4EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0 M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6 MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L# M!!0 ( !&(>50<.&7J/P$ #P" / >&PO=V]R:V)O;VLN>&ULC5'+ M;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2=8C%/B*O RU?7R=15*1>>O)Z;(UG M9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-;"#(I(KD#4M+ARPU!,:F&H"]RZ9Y M/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]SKM6G3#A'AWR=Z'[MP.M/ ;T> %; MZ%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE'WC;B?PT^]0C;/8?1H04>I8+8864 MN-_H^8UH/($L#UW+\0D= ZT,PS/%ML%PZ&C$179EH\]AK$.(<_I/C+&JL(15 M+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ#"PAJ748J&2WEYIK=WDWM)J'7N0;#W\!J-'[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD M3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\, M<'AT_@%02P,$% @ $8AY5&60>9(9 0 SP, !, !;0V]N=&5N=%]4 M>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-. MVDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B M2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5* M$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I: MP'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$Y ML01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\; MSO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " 1B'E4!T%-8H$ "Q M $ @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 M ( !&(>50("WSM[0 "L" 1 " :\ !D;V-05297)PC$ 8 )PG 3 M " &UL4$L! A0#% @ $8AY M5.$$P#I/! 8! !@ ("!# @ 'AL+W=O52?H!OPL0( .(, - M " 9$, !X;"]S='EL97,N>&UL4$L! A0#% @ $8AY5)>*NQS M $P( L ( !;0\ %]R96QS+RYR96QS4$L! A0#% M @ $8AY5!PX9>H_ 0 / ( \ ( !5A 'AL+W=O50D'INBK0 /@! : M " <(1 !X;"]?51ED'F2&0$ ,\# 3 " :<2 !;0V]N=&5N=%]4 ?>7!E&UL4$L%!@ ) D /@( /$3 $! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adpt-8k_20220325.htm adpt-20220325.xsd adpt-20220325_lab.xml adpt-20220325_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adpt-8k_20220325.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "adpt-8k_20220325.htm" ] }, "labelLink": { "local": [ "adpt-20220325_lab.xml" ] }, "presentationLink": { "local": [ "adpt-20220325_pre.xml" ] }, "schema": { "local": [ "adpt-20220325.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20220325", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20220325.htm", "contextRef": "C_0001478320_20220325_20220325", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20220325.htm", "contextRef": "C_0001478320_20220325_20220325", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.adaptivebiotech.com/20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001564590-22-011827-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-011827-xbrl.zip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end